Popular brands like Prilosec, Nexium, and Prevacid are often taken daily to reduce stomach acid and help manage conditions ...

In Virginia, health statistics show more than 20,000 people depend on dialysis and just a few thousand fewer have had kidney ...

Sponsor: Kidneys for Communities Kidney disease is one of the leading causes of death in America, with nearly 100,000 people ...

Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Doctors typically treat Hirschsprung disease with surgery to remove part of the intestine. Learn about surgical procedures, ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

In patients with CKD, hyperkalemia significantly increases risk for major adverse cardiovascular events and arrhythmia.

Study findings support the monitoring and management of iron status in patients with early stages of chronic kidney disease (CKD).